_JBW5487.2.jpg

INTRODUCING THE BREAKTHROUGH TECHNOLOGY OF THE BETACURVE™,
designed to target the unmet needs of people with wet-AMD. 

Millions suffer vision loss from PCV (polypoidal choroidal vasculopathy),
a sub-type of wet-AMD 
(advanced age-related macular degeneration).

Advanced age-related macular degeneration (wet-AMD) is the leading cause of vision loss in seniors globally.

CURRENT TREATMENT

Expensive, frequent, lifelong injections directly into the eye of anti-VEGF (anti-vascular endothelial growth factor) is the standard of care.

More than half of patients treated with injections still suffer inadequate results.

INTRODUCING BETACURVE

SAVING VISION WITH PRECISION BETA RADIATION

SalutarisMD®  [SMD] is a clinical stage medical device company.  SMD's BetaCurve is a globally-patented, 510(k)-cleared device designed to treat various ophthalmic diseases with precision beta radiotherapy, including PCV.

The BetaCurve™ curves around the back of the eye to precisely deliver therapeutic beta radiation to the diseased area using a fiber optic light source for placement guidance.

The procedure is a outpatient, takes 10-minutes, and requires only one treatment. Utilizing a common technique, retina surgeons do not require additional methodological training.

_JBW5553.2 .jpg

PATENTED TECHNOLOGY

IP Portfolio Summary

Global patents protect

both the device and methods

for SMD’s precision delivery platform

 

Key patents granted in 50+ countries

 

 

BetaCurve is FDA 510k-cleared & ISO compliant

patent.png

6    TRADEMARKS  
13    DESIGN PATENTS
73   UTILITY PATENTS

CUTTING EDGE DESIGN FEATURES

SAFE TREATMENT

BetaCurve applies the well-established, therapeutic approach of low-dose beta radiation.

 

MINIMALLY INVASIVE

Our episcleral brachytherapy is an outpatient procedure using twilight anesthesia with minimal discomfort.

 

ACCURATE DOSIMETRY

The individualized treatment time ensures an accurate dose of beta radiotherapy.

 

PRECISION TARGETING

The retina surgeon targets the offending lesion with a precision beta radiotherapy delivery platform

A PROMISING ALTERNATIVE FOR THOSE PATIENTS WHO DO NOT RESPOND WELL TO ANTI-VEGF

CURRENT TREATMENT: 
Anti-VEGF 

  • Effective against classic wet-AMD, the type that primarily affects lightly pigmented individuals,  especially Whites.

  • Improvement in vision is palliative due to underlying persistent disease activity             

  • Requires a lifetime of injections (monthly for recalcitrant subtypes) 

  • A temporary solution as patients often quit injections as early results fade or they develop drug resistance over time

NEW PROSPECTIVE TREATMENT:
BetaCurve

*

  • Future pivotal trial to show efficacy against PCV, the type that primarily affects pigmented individuals, especially Asians and Blacks

  • Designed to reduce or eliminate underlying disease 

  • One-time treatment may reduce or eliminate injections altogether for all subtypes                         

  • Radiotherapy may prove to be durable and last a lifetime

  • Minimally-invasive, one-time procedure

SalutarisMD saving vision for everyone
crosshair-146621_edited_edited.png

MISSION

Saving vision for everyone

At SalutarisMD, our mission is to make treatment for AMD and other challenging retina diseases available to all, no matter the economic status or geographic location – an affordable, accessible, one-time treatment that can last a lifetime.

Frequent visits for anti-VEGF injection is not practical in many countries. One-time SMD precision radiotherapy can be made available everywhere.